Abata Therapeutics
15 articles about Abata Therapeutics
-
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events
8/28/2023
Abata Therapeutics, a company focused on translating the biology of regulatory T cells into transformational medicines for patients living with severe autoimmune and inflammatory diseases, announced that company leadership will present and participate in the following investor and industry events.
-
Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes
8/24/2023
Abata Therapeutics today announced its second development candidate, ABA-201, which has the potential to be a disease-modifying Treg cell therapy for patients with type 1 diabetes (T1D) who have remaining beta (β) cell function.
-
Abata Therapeutics to Present at Upcoming Investor and Industry Events in June
5/31/2023
Abata Therapeutics today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June.
-
Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer
4/20/2023
Abata Therapeutics today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
-
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors
3/9/2023
Abata Therapeutics today announced the appointment of David Kaufman, M.D., Ph.D., partner at Third Rock Ventures, to its board of directors.
-
Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer
12/7/2022
Abata Therapeutics today announced that it has appointed Ellen Cahir-McFarland, Ph.D., as its Chief Scientific Officer.
-
Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day
11/9/2022
Abata Therapeutics today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer, and John Trzupek, M.B.A., Ph.D., chief operating officer, will participate in a fireside chat at Guggenheim’s 4th Annual Immunology and Neurology Day on Monday, November 14, 2022, at 9:00 a.m. ET in New York, NY.
-
Abata Therapeutics to Present at Upcoming September Investor Conferences
8/31/2022
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer of Abata will participate in the following investor conferences.
-
Abata Therapeutics to Participate in the Guggenheim I&I Spotlight Series – Treg-Based Therapies
7/6/2022
Abata Therapeutics announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer, and John Trzupek, M.B.A., Ph.D., chief operating officer of Abata will participate in a fireside chat at the Guggenheim I&I Spotlight Series – Treg-Based Therapies on Tuesday, July 12, 2022, at 9:35 a.m. ET in New York, NY.
-
Abata Therapeutics to Present at Upcoming Investor Conferences
6/2/2022
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer of Abata will participate in the following investor conferences in New York, NY.
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, April 8
4/8/2022
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week. -
Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development
4/6/2022
Abata Therapeutics today announced the formation of the Abata Advisory Board, chaired by Diane Mathis, Ph.D., co-founder of Abata.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
The Third Rock Ventures-backed startup has a pipeline of Treg therapeutics aimed at multiple sclerosis, type 1 diabetes and inclusion body myositis.